Pure Global
NCT06138210

The Effect of GD-iExo-003 in Acute Ischemic Stroke

The Effect of Exosomes Derived From Human Induced Pluripotent Stem Cell (GD-iExo-003) in Acute Ischemic Stroke: an Exploratory Study.
Xuanwu Hospital, Beijing·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
exosomes derived from human induced pluripotent stem cell for injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Xuanwu Hospital, Beijing
Timeline & enrollment
Phase
Phase 1
Start date
Jan 30, 2024
End date
Aug 30, 2025
Enrollment
29 participants
Primary outcome

Number of participants who experienced dose-limiting Toxicities (DLTs)

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial.
 The objective of this study is evaluating safety and preliminary efficacy of intravenous
 exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic
 stroke.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06138210
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06138210 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xuanwu Hospital, Beijing and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 29 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.